Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
REGN17092 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Cohort 1 Mid IV Dose | EXPERIMENTAL | Randomized 6:2 for single ascending dose |
| Cohort 3 High IV Dose | EXPERIMENTAL | Randomized 6:2 for single ascending dose |
| Cohort 5 Higher IV Dose | EXPERIMENTAL | Randomized 6:2 for single ascending dose |
| Cohort 6 Low IV Dose | EXPERIMENTAL | Randomized 6:2 for single ascending dose |
| Cohort 2 Mid SC Dose | EXPERIMENTAL | Randomized 6:2 for single ascending dose |
| Cohort 4 High SC Dose | EXPERIMENTAL | Randomized 6:2 for single ascending dose |
| Cohort 7 Low SC Dose | EXPERIMENTAL | Randomized 6:2 for single ascending dose |
| Expansion Cohort 1 | EXPERIMENTAL | Randomized 3:1 for single ascending dose |
| Expansion Cohort 2 | EXPERIMENTAL | Randomized 3:1 for single ascending dose |
| Expansion Cohort 3 | EXPERIMENTAL | Randomized 3:1 for single ascending dose |
| Name | Type | Description |
|---|---|---|
| REGN17092 | DRUG | Single ascending intravenous (IV) or subcutaneous (SC) administration per the protocol |
| Matching Placebo | DRUG | Single ascending IV or SC administration per the protocol |
Key Inclusion Criteria: 1. Has a SARS-CoV-2 negative test result from a sample collected ≤72 hours prior to randomization as described in the protocol 2. Has received complete primary series of standard-of-care COVID-19 vaccination per local guidance, completed at least 2 weeks prior to screening 3...
REGN17092 is an investigational small molecule being developed by Regeneron Pharmaceuticals, Inc. It is currently in Phase 1 clinical development. The drug has been studied in healthy volunteers to assess its safety, and it is not yet approved for any medical use.
REGN17092 is being studied for use in healthy volunteers. The completed Phase 1 trial aimed to evaluate the safety of different doses of the drug in healthy adults. It is an investigational agent and has not been approved for any specific disease or condition.
REGN17092 is being developed by Regeneron Pharmaceuticals, Inc., a biopharmaceutical company traded on NASDAQ under the ticker REGN. Regeneron is conducting clinical research on this investigational small molecule.
REGN17092 is in Phase 1 clinical development. A Phase 1 trial has been completed, which focused on evaluating the safety of different doses in healthy adults. The drug remains investigational and has not received regulatory approval.
REGN17092 has one completed Phase 1 clinical trial, registered as NCT05923424. This trial, titled "A Trial to Learn if Different Doses of REGN17092 Are Safe in Healthy Adults," enrolled 40 participants in Belgium. The study was randomized, double-blind, and controlled.
REGN17092 is not FDA approved. It is an investigational drug that has completed a Phase 1 trial in healthy volunteers. The drug is still in clinical development and has not been authorized for any medical use.